NCT02329717View on ClinicalTrials.gov

Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Pancreatic Cancer
Interventions
DRUG

PBI 05204

PBI 05204 daily dosing

Trial Locations (5)

22031

Virginia Cancer Specialists, Fairfax

33613

Florida Hospital Tampa, Tampa

37232

Vanderbilt University Medical Center, Nashville

85258

Scottsdale Healthcare Hospitals, Scottsdale

98111

Virginia Mason Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Phoenix Biotechnology, Inc

INDUSTRY

NCT02329717 - Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter